Pyronaridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Pyronaridine is a benzonaphthyridine derivative indicated in the treatment of acute malaria caused by P. falciparum or P. vivax in area with low rates of infection and low resistance to artemisinin.

Generic Name
Pyronaridine
DrugBank Accession Number
DB12975
Background

Pyronaridine has been investigated for the treatment of Malaria.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 518.06
Monoisotopic: 517.224453
Chemical Formula
C29H32ClN5O2
Synonyms
  • Pyronaridine

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcute falciparum malaria•••••••••••••••••• •••••••••••• •••••• ••• ••••••••
Treatment ofAcute malaria caused by plasmodium vivax•••••••••••••••••• •••••••••••• •••••• ••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetophenazineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Acetophenazine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Alimemazine.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Pyronaridine is combined with Ambroxol.
ArtemetherThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Artemether.
ArticaineThe risk or severity of methemoglobinemia can be increased when Pyronaridine is combined with Articaine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Pyronaridine tetraphosphate2T289F9ACONot AvailableYKUQEKXHQFYULM-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PYRAMAX TABLETSPyronaridine tetraphosphate (180 MG) + Artesunate (60 MG)Tablet, film coatedบริษัท ดีซีเอฟ เฮลท์แคร์ จำกัด2017-10-10Not applicableThailand flag

Categories

ATC Codes
P01BF06 — Artesunate and pyronaridine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Aminoquinolines and derivatives
Direct Parent
4-aminoquinolines
Alternative Parents
Chloroquinolines / Naphthyridines / p-Aminophenols / Aniline and substituted anilines / Phenylmethylamines / Benzylamines / Alkyl aryl ethers / Aminopyridines and derivatives / Aralkylamines / Primary aromatic amines
show 8 more
Substituents
4-aminoquinoline / Alkyl aryl ether / Amine / Aminophenol / Aminopyridine / Aniline or substituted anilines / Aralkylamine / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
TD3P7Q3SG6
CAS number
74847-35-1
InChI Key
DJUFPMUQJKWIJB-UHFFFAOYSA-N
InChI
InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)
IUPAC Name
4-({7-chloro-2-methoxybenzo[b]1,5-naphthyridin-10-yl}amino)-2,6-bis[(pyrrolidin-1-yl)methyl]phenol
SMILES
COC1=NC2=C(NC3=CC(CN4CCCC4)=C(O)C(CN4CCCC4)=C3)C3=CC=C(Cl)C=C3N=C2C=C1

References

General References
Not Available
PubChem Compound
5485198
PubChem Substance
347829115
ChemSpider
10647812
BindingDB
53353
ChEBI
135951
ChEMBL
CHEMBL35228
ZINC
ZINC000003882897
Wikipedia
Pyronaridine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentMalaria1
4CompletedTreatmentMalaria caused by Plasmodium falciparum1
4Not Yet RecruitingTreatmentBurkina Faso / Malaria1
4RecruitingTreatmentPlasmodium Falciparum Malaria (Drug Resistant)1
3CompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / Malaria1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coated
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0132 mg/mLALOGPS
logP5.78ALOGPS
logP4.22Chemaxon
logS-4.6ALOGPS
pKa (Strongest Acidic)7.96Chemaxon
pKa (Strongest Basic)10.08Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area73.75 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity147.74 m3·mol-1Chemaxon
Polarizability57.85 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0000090000-b91b1ac514078fef9273
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-2010390000-4242c80b742338cad973
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0009300000-0f9d5423e010a8a823da
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00o0-9004280000-9d5a29c0be0e4feaf762
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0159-2009120000-1992be0107c947e53f7a
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9105810000-8a406fbeb29d84cae0a6
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-223.97961
predicted
DeepCCS 1.0 (2019)
[M+H]+226.33762
predicted
DeepCCS 1.0 (2019)
[M+Na]+232.43077
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 01:44 / Updated at June 12, 2021 10:54